Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Multi-Center Single Arm Clinical Trial to Study the Efficacy and Safety of the Elbasvir/ Grazoprevir 50/100 mg Fixed Dose Combination Once Daily in Patients With Chronic HCV GT1b Infection Associated With Metabolic Syndrome

NCT03222167 is registered in ClinicalTrials.gov with Institute Of Cardiology & Internal Diseases, Kazakhstan as lead sponsor.

NCT NCT03222167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03222167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Multi-Center Single Arm Clinical Trial to Study the Efficacy and Safety of the Elbasvir/ Grazoprevir 50/100 mg Fixed Dose Combination Once Daily in Patients With Chronic HCV GT1b Infection Associated With Metabolic Syndrome
Lead sponsor
Institute Of Cardiology & Internal Diseases, Kazakhstan
Phase
Phase 3
Overall status
Unknown status
Start date
October 31, 2017
Completion date
August 31, 2019
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c genotype 1b, cirrhoses, liver, fibrosis, liver, metabolic syndrome